Evidence map›Paper›PMID 35305665›Full record

ArticleJournal of nanobiotechnology2022

GSK-3β suppression upregulates Gli1 to alleviate osteogenesis inhibition in titanium nanoparticle-induced osteolysis.

Qing Wang, Wei Zhang, Xiaole Peng, Yunxia Tao, Ye Gu, Wenming Li, Xiaolong Liang, Liangliang Wang, Zerui Wu, Tianhao Wang and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of nanobiotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 3 institutions in 1 country.

Qing Wang *Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Wei Zhang *Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Xiaole Peng *Department of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yunxia TaoDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Ye GuDepartment of Orthopaedics, Changshu Hospital Affiliated to Soochow University, First People's Hospital of Changshu City, Changshu, China.
Wenming LiDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Xiaolong LiangDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Liangliang WangDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Zerui WuDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Tianhao WangDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Haifeng ZhangDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Xin LiuDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China.
Yaozeng XuDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. xuyaozeng@163.com.
Yu LiuDepartment of Orthopaedics, Wuxi Ninth People's Hospital Affiliated to Soochow University, Wuxi, 214062, China. wxsjyly@126.com.
Jun ZhouDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. zhou.jun.roy@hotmail.com.
Dechun GengDepartment of Orthopaedics, The First Affiliated Hospital of Soochow University, Suzhou, 215006, China. szgengdc@suda.edu.cn.
Soochow University · CNFirst Affiliated Hospital of Soochow University · CNXuzhou Medical College · CN

Funding

Jiangsu Agricultural Science and Technology Independent Innovation Fund H2019024National Natural Science Foundation of China 81672238National Natural Science Foundation of China 81770327National Natural Science Foundation of China 81873990National Natural Science Foundation of China 81873991National Natural Science Foundation of China 82072498National Natural Science Foundation of China Nos. 82072425Natural Science Foundation of Jiangsu Province BE2021650Natural Science Foundation of Jiangsu Province BK20200198Natural Science Foundation of Jiangsu Province Nos. BK20180001Special Project of Diagnosis and Treatment Technology for Key Clinical Diseases in Suzhou LCZX201824Special Project of Diagnosis and Treatment Technology for Key Clinical Diseases in Suzhou LCZX202003the Application Fundamental Research Program of Suzhou City SYS2018032the Colleges and Universities Natural Science Foundation in Jiangsu Province 19KJB320019the Young Medical Talents of Jiangsu Province No. QNRC2016751
6 · The paper itself

Abstract

Wear particle-induced periprosthetic osteolysis (PPO) have become a major reason of joint arthroplasty failure and secondary surgery following joint arthroplasty and thus pose a severe threat to global public health. Therefore, determining how to effectively suppress particle-induced PPO has become an urgent problem. The pathological mechanism involved in the PPO signaling cascade is still unclear. Recently, the interaction between osteogenic inhibition and wear particles at the implant biological interface, which has received increasing attention, has been revealed as an important factor in pathological process. Additionally, Hedgehog (Hh)-Gli1 is a crucial signaling cascade which was regulated by multiple factors in numerous physiological and pathological process. It was revealed to exert a crucial part during embryonic bone development and metabolism. However, whether Hh-Gli1 is involved in wear particle-induced osteogenic inhibition in PPO remains unknown. Our present study explored the mechanism by which the Hh-Gli1 signaling cascade regulates titanium (Ti) nanoparticle-induced osteolysis. We found that Hh-Gli1 signaling was dramatically downregulated upon Ti particle treatment. Mechanistically, glycogen synthesis kinase 3β (GSK-3β) activation was significantly increased in Ti particle-induced osteogenic inhibition via changes in GSK-3β phosphorylation level and was found to participate in the posttranslational modification and degradation of the key transcription factor Gli1, thus decreasing the accumulation of Gli1 and its translocation from the cytoplasm to the nucleus. Collectively, these findings suggest that the Hh-Gli1 signaling cascade utilizes a GSK3β-mediated mechanism and may serve as a rational new therapeutic target against nanoparticle-induced PPO.

Indexed as

NanoparticlesOsteolysisGlycogen Synthase Kinase 3 betaHedgehog ProteinsHumansOsteogenesisTitaniumZinc Finger Protein GLI1GLI1 protein, humanGlycogen Synthase Kinase 3 betaGSK3B protein, humanHedgehog ProteinsTitaniumZinc Finger Protein GLI1Bone formationHedgehog signaling pathwayOsteogenesisPeriprosthetic osteolysisTitanium nanoparticles

Identifiers

PMID35305665
PMCPMC8934501
OpenAlexW4220692982

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.